Habe eher den Eindruck dass du bei den Fakten nicht auf dem aktuellen Stand bist. Hier die entscheidende Aussage im Conference Call vom 30.07.2021.
"Pelabresib has shown a strong response rate in combination with ruxolitinib, achieving a spleen volume reduction in 67% of first-line myelofibrosis patients. It has also shown strong data in the second-line or third-line myelofibrosis. This data makes us very confident about the success of the ongoing global Phase III study, MANIFEST TWO. It is a randomized study comparing Pelabresib plus ruxolitinib against ruxolitinib alone in front-line myelofibrosis. During our due diligence process prior to the acquisition, we looked carefully into every aspect of Constellation's clinical development programs, specifically the MANIFEST TWO study.
Based on our detailed assessment, we decided to optimize the trial design to raise its overall probability of success, by increasing the number of trial participants to approximately 400 patients. We will also improve the speed of enrollment and have already launched a mitigation plan, ensuring operational excellence. This includes adding additional CROs, improving interaction with investigators, expanding the number of countries and sites, and other measures. With all activities in place, we expect to report topline data from this study in the first half of 2024."